Seattle biotech AltPep closes $23M funding round for Alzheimer ’s research
Seattle biotech AltPep Corp. closed a $23 million series A funding round last week, which will go toward its Alzheimer ’s research.
The biotech is a portfolio company of IntuitiveX, a Seattle life science incubator. Altpep's board of directors also made several additions, including Adaptive Biotechnologies CEO Chad Robins; David Goel, managing general partner and founded of Matrix Capital Management; and Joel Mar cus, executive chairman and founder of Alexandria Real Estate Equities and Alexandria…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Megan Campbell Source Type: news
More News: Alzheimer's | Biotechnology | Chad Health | Funding | Health Management | Pharmaceuticals | Science